Nomura $230 price target
Sarepta analyst commentary at Nomura Instinet Sarepta has 'signficant upside catalysts ahead,' says Nomura Instinet. Nomura Instinet analyst Christopher Marai sees "significant upside catalysts ahead into mid-2020" for Sarepta Therapeutics. Ahead of the company's Q3 results on November 7 he keeps a Buy rating on the shares with a $230 price target. The analyst thinks Golodirsen's Complete Response Letter will likely be resolved in the near-term and that Sarepta's "valuation floor" is based on its current exon skipping platform.
Source Thefly
High Call options traded pre earnings.
Indicators bullish and volume increasing.
Short squeeze potential with a very high 22.14% short interest.
Company profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Sarepta analyst commentary at Nomura Instinet Sarepta has 'signficant upside catalysts ahead,' says Nomura Instinet. Nomura Instinet analyst Christopher Marai sees "significant upside catalysts ahead into mid-2020" for Sarepta Therapeutics. Ahead of the company's Q3 results on November 7 he keeps a Buy rating on the shares with a $230 price target. The analyst thinks Golodirsen's Complete Response Letter will likely be resolved in the near-term and that Sarepta's "valuation floor" is based on its current exon skipping platform.
Source Thefly
High Call options traded pre earnings.
Indicators bullish and volume increasing.
Short squeeze potential with a very high 22.14% short interest.
Company profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.